The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a huge mover today! About 1.66 million shares traded hands. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has risen 38.91% since March 9, 2016 and is uptrending. It has outperformed by 31.50% the S&P500.
The move comes after 5 months negative chart setup for the $3.05 billion company. It was reported on Oct, 12 by Barchart.com. We have $23.71 PT which if reached, will make NASDAQ:ACAD worth $244.00M less.
Analysts await ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to report earnings on November, 3. They expect $-0.60 EPS, down 53.85% or $0.21 from last year’s $-0.39 per share. After $-0.63 actual EPS reported by ACADIA Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts -4.76% EPS growth.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Ratings Coverage
Out of 4 analysts covering ACADIA Pharmaceuticals (NASDAQ:ACAD), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. ACADIA Pharmaceuticals has been the topic of 13 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The firm has “Overweight” rating by Piper Jaffray given on Friday, January 22. Cowen & Co maintained the stock with “Outperform” rating in Sunday, August 9 report. The company was downgraded on Tuesday, May 3 by Leerink Swann. The firm has “Neutral” rating given on Friday, August 7 by Piper Jaffray. The rating was initiated by Leerink Swann with “Mkt Perform” on Tuesday, October 4. As per Friday, August 7, the company rating was downgraded by Piper Jaffray. The firm has “Buy” rating by JP Morgan given on Friday, September 4. Needham maintained ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) rating on Friday, August 7. Needham has “Buy” rating and $49 price target. Piper Jaffray upgraded ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on Thursday, August 27 to “Neutral” rating. Vetr upgraded the shares of ACAD in a report on Monday, August 10 to “Hold” rating.
According to Zacks Investment Research, “Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson’s disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.”
Insitutional Activity: The institutional sentiment decreased to 1.02 in 2016 Q2. Its down 0.31, from 1.33 in 2016Q1. The ratio dropped, as 32 funds sold all ACADIA Pharmaceuticals Inc. shares owned while 68 reduced positions. 41 funds bought stakes while 61 increased positions. They now own 104.57 million shares or 4.71% less from 109.74 million shares in 2016Q1.
Principal Fin Grp Inc Inc Inc holds 0% or 19,013 shares in its portfolio. The New York-based Teachers Advsrs Inc has invested 0.01% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Cubist Systematic Strategies Ltd Com, a Connecticut-based fund reported 17,330 shares. Winslow Evans Crocker owns 4,400 shares or 0% of their US portfolio. Employees Retirement Association Of Colorado accumulated 0.01% or 22,365 shares. Invesco Ltd last reported 1.15 million shares in the company. Moreover, Eventide Asset Ltd Liability has 0.66% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 334,700 shares. Voya Inv Mngmt Ltd Liability Company has 0.06% invested in the company for 716,858 shares. Veritable Ltd Partnership accumulated 6,778 shares or 0.01% of the stock. Raymond James Associate reported 8,644 shares or 0% of all its holdings. Wellington Mgmt Ltd Liability Partnership last reported 0% of its portfolio in the stock. Da Davidson & Communication accumulated 500 shares or 0% of the stock. The Ontario – Canada-based National Bank Of Montreal Can has invested 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Axa accumulated 166,244 shares or 0.02% of the stock. Price T Rowe Md holds 0.05% or 7.12 million shares in its portfolio.
Insider Transactions: Since April 18, 2016, the stock had 2 insider purchases, and 2 sales for $41.34 million net activity. The insider Iversen Leslie L sold 33,697 shares worth $1.13 million. On Wednesday, August 10 the insider BAKER BROS. ADVISORS LP bought $43.00M. 1,000 shares were bought by HARRIGAN EDMUND, worth $32,970 on Tuesday, August 16. 16,000 shares were sold by Baity Glenn, worth $560,033 on Monday, July 11.
Another recent and important ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) news was published by Schaeffersresearch.com which published an article titled: “Options Traders Bet On ACADIA Pharmaceuticals Inc. (ACAD) Breaking Lower” on September 30, 2016.
ACAD Company Profile
ACADIA Pharmaceuticals Inc., incorporated on January 16, 1997, is a biopharmaceutical company. The Firm is focused on the development and commercialization of medicines for central nervous system disorders. The Company’s lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson’s disease psychosis (PDP).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.